Th17 cytokines: Novel potential therapeutic targets for COPD pathogenesis and exacerbations

European Respiratory Journal

Volumn 50, Issue 4, 2017, Pages

  Le Rouzic, Olivier ^a,b,c,d,e   Pichavant, Muriel ^a,b,c,d   Frealle, Emilie ^a,b,c,d,e   Guillon, Antoine ^f,g,h   Si Tahar, Mustapha ^g,h   Gosset, Philippe ^a,b,c,d  

^a UNIV LILLE   (France)

^b CNRS   (France)

^c INSERM U1019   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g Université Franaois Rabelais   (France)

^h UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

AIRWAY OBSTRUCTION; ANTIGEN PRESENTING CELL; CELL ACTIVATION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMPHYSEMA; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFECTION SENSITIVITY; LUNG FUNCTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STEADY STATE; TH17 CELL; DRUG DEVELOPMENT; DRUG EFFECT; IMMUNITY; IMMUNOLOGY;

DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; IMMUNITY; INTERLEUKIN-17; INTERLEUKINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85031699271     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02434-2016     Document Type: Review

References (111)

1. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. http://goldcopd.org. Date last accessed: June 1, 2017. Date last updated: January 1, 2017.
2. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015; 5: 020415.
3. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
4. Pavord ID, Jones PW, Burgel P-R, et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 21-30.
5. Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 195: 324-330.
6. McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 2014; 260: 129-144.
7. Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. Vaccine 2016; 34: 1504-1514.
8. Iwasaki A, Foxman EF, Molony RD. Early local immune defences in the respiratory tract. Nat Rev Immunol 2017; 17: 7-20.
9. Pappu R, Rutz S, Ouyang W. Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol 2012; 33: 343-349.
10. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252: 116-132.
11. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014; 13: 21-38.
12. Kreindler JL, Bertrand CA, Lee RJ, et al. Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 296: L257-L266.
13. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487: 109-113.
14. Liang SC, Long AJ, Bennett F, et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007; 179: 7791-7799.
15. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14: 275-281.
16. Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010; 207: 1293-1305.
17. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity 2015; 43: 1040-1051.
18. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-1397.
19. Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13: 991-999.
20. Andelid K, Tengvall S, Andersson A, et al. Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization? Int J Chron Obstruct Pulmon Dis 2015; 10: 689-702.
21. Jin Y, Wan Y, Chen G, et al. Treg/IL-17 ratio and Treg differentiation in patients with COPD. PLoS One 2014; 9: e111044.
22. Sun N, Wei X, Wang J, et al. Caveolin-1 promotes the imbalance of Th17/Treg in patients with chronic obstructive pulmonary disease. Inflammation 2016; 39: 2008-2015.
23. Wang H, Ying H, Wang S, et al. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin Respir J 2015; 9: 330-341.
24. Zhang L, Cheng Z, Liu W, et al. Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD 2013; 10: 459-465.
25. Zou Y, Chen X, Liu J, et al. Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters. Int J Chron Obstruct Pulmon Dis 2017; 12: 1247-1254.
26. Imani S, Salimian J, Fu J, et al. Th17/Treg-related cytokine imbalance in sulfur mustard exposed and stable chronic obstructive pulmonary (COPD) patients: correlation with disease activity. Immunopharmacol Immunotoxicol 2016; 38: 270-280.
27. Li H, Liu Q, Jiang Y, et al. Disruption of Th17/Treg balance in the sputum of patients with chronic obstructive pulmonary disease. Am J Med Sci 2015; 349: 392-397.
28. Li X-N, Pan X, Qiu D. Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage. Int J Clin Exp Med 2014; 7: 5324-5329.
29. Paats MS, Bergen IM, Hoogsteden HC, et al. Systemic CD4+ and CD8+ T-cell cytokine profiles correlate with GOLD stage in stable COPD. Eur Respir J 2012; 40: 330-337.
30. Qiu S-L, Duan M-C, Liang Y, et al. Cigarette smoke induction of interleukin-27/WSX-1 regulates the differentiation of Th1 and Th17 cells in a smoking mouse model of emphysema. Front Immunol 2016; 7: 553.
31. Solleiro-Villavicencio H, Quintana-Carrillo R, Falfán-Valencia R, et al. Chronic obstructive pulmonary disease induced by exposure to biomass smoke is associated with a Th2 cytokine production profile. Clin Immunol 2015; 161: 150-155.
32. Vargas-Rojas MI, Ramírez-Venegas A, Limón-Camacho L, et al. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med 2011; 105: 1648-1654.
33. Xu W-H, Hu X-L, Liu X-F, et al. Peripheral Tc17 and Tc17/interferon-γ cells are increased and associated with lung function in patients with chronic obstructive pulmonary disease. Chin Med J 2016; 129: 909-916.
34. Zhang J-C, Chen G, Chen L, et al. TGF-β/BAMBI pathway dysfunction contributes to peripheral Th17/Treg imbalance in chronic obstructive pulmonary disease. Sci Rep 2016; 6: 31911.
35. Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, et al. Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax 2013; 68: 330-337.
36. Barczyk A, Pierzchala W, Sozañska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003; 97: 726-733.
37. Doe C, Bafadhel M, Siddiqui S, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010; 138: 1140-1147.
38. Eustace A, Smyth LJC, Mitchell L, et al. Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. Chest 2011; 139: 1089-1100.
39. Moermans C, Bonnet C, Willems E, et al. Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. Bone Marrow Transplant 2014; 49: 1382-1388.
40. Roos AB, Sethi S, Nikota J, et al. IL-17A and the promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 428-437.
41. Chang Y, Nadigel J, Boulais N, et al. CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease. Respir Res 2011; 12: 43.
42. Chu S, Zhong X, Zhang J, et al. The expression of Foxp3 and ROR gamma t in lung tissues from normal smokers and chronic obstructive pulmonary disease patients. Int Immunopharmacol 2011; 11: 1780-1788.
43. Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009; 157: 316-324.
44. Montalbano AM, Riccobono L, Siena L, et al. Cigarette smoke affects IL-17A, IL-17F and IL-17 receptor expression in the lung tissue: ex vivo and in vitro studies. Cytokine 2015; 76: 391-402.
45. Roos AB, Sandén C, Mori M, et al. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med 2015; 191: 1232-1241.
46. Zhang J, Chu S, Zhong X, et al. Increased expression of CD4+IL-17+ cells in the lung tissue of patients with stable chronic obstructive pulmonary disease (COPD) and smokers. Int Immunopharmacol 2013; 15: 58-66.
47. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
48. Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated lymphoid tissue: taming inflammation in the lung. Front Immunol 2016; 7: 258.
49. Yadava K, Pattaroni C, Sichelstiel AK, et al. Microbiota promotes chronic pulmonary inflammation by enhancing il-17a and autoantibodies. Am J Respir Crit Care Med 2016; 193: 975-987.
50. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol 2017; 18: 104-113.
51. Bagdonas E, Raudoniute J, Bruzauskaite I, et al. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 995-1013.
52. Lee S-H, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
53. Kuo Y-B, Chang CA, Wu Y-K, et al. Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. Immunol Lett 2010; 128: 131-136.
54. Zhou H, Hua W, Jin Y, et al. Tc17 cells are associated with cigarette smoke-induced lung inflammation and emphysema. Respirology 2015; 20: 426-433.
55. Bozinovski S, Seow HJ, Chan SPJ, et al. Innate cellular sources of interleukin-17A regulate macrophage accumulation in cigarette-smoke-induced lung inflammation in mice. Clin Sci 2015; 129: 785-796.
56. Pichavant M, Rémy G, Bekaert S, et al. Oxidative stress-mediated iNKT-cell activation is involved in COPD pathogenesis. Mucosal Immunol 2014; 7: 568-578.
57. Wang J, Urbanowicz RA, Tighe PJ, et al. Differential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD). PLoS One 2013; 8: e58556.
58. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
59. Kalathil SG, Lugade AA, Pradhan V, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 190: 40-50.
60. Sharan R, Perez-Cruz M, Kervoaze G, et al. Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease. Mucosal Immunol 2017; 10: 139-149.
61. Tashkin DP, Altose MD, Bleecker ER, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145: 301-310.
62. Wise RA, Kanner RE, Lindgren P, et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest 2003; 124: 449-458.
63. Hassan NM, Hargreave FE, Nair P. Airway responsiveness to indirect challenges in COPD. COPD 2010; 7: 133-140.
64. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J 2012; 40: 1098-1105.
65. Kim HY, Lee HJ, Chang Y-J, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med 2014; 20: 54-61.
66. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011; 38: 1019-1028.
67. Pichavant M, Goya S, Meyer EH, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med 2008; 205: 385-393.
68. Li J, Zhou W, Huang K, et al. Interleukin-22 exacerbates airway inflammation induced by short-term exposure to cigarette smoke in mice. Acta Pharmacol Sin 2014; 35: 1393-1401.
69. McGovern TK, Goldberger M, Allard B, et al. Neutrophils mediate airway hyperresponsiveness after chlorine-induced airway injury in the mouse. Am J Respir Cell Mol Biol 2015; 52: 513-522.
70. Yanagisawa H, Hashimoto M, Minagawa S, et al. Role of IL-17A in murine models of COPD airway disease. Am J Physiol Lung Cell Mol Physiol 2017; 312: L122-L130.
71. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8: 183-192.
72. Harrison OJ, Foley J, Bolognese BJ, et al. Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol Lett 2008; 121: 13-21.
73. Bracke KR, D’hulst AI, Maes T, et al. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006; 177: 4350-4359.
74. Chen K, Pociask DA, McAleer JP, et al. IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS One 2011; 6: e20333.
75. Lu W, You R, Yuan X, et al. The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema. Nat Immunol 2015; 16: 1185-1194.
76. Kurimoto E, Miyahara N, Kanehiro A, et al. IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice. Respir Res 2013; 14: 5.
77. Fujii U, Miyahara N, Taniguchi A, et al. IL-23 is essential for the development of elastase-induced pulmonary inflammation and emphysema. Am J Respir Cell Mol Biol 2016; 55: 697-707.
78. Overbeek SA, Braber S, Koelink PJ, et al. Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One 2013; 8: e55612.
79. Chang Y, Al-Alwan L, Audusseau S, et al. Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis. Am J Physiol Lung Cell Mol Physiol 2014; 306: L132-L143.
80. Ivanov S, Fontaine J, Paget C, et al. Key role for respiratory CD103+ dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide. J Infect Dis 2012; 206: 723-734.
81. Ivanov S, Renneson J, Fontaine J, et al. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J Virol 2013; 87: 6911-6924.
82. Wozniak KL, Hole CR, Yano J, et al. Characterization of IL-22 and antimicrobial peptide production in mice protected against pulmonary Cryptococcus neoformans infection. Microbiology 2014; 160: 1440-1452.
83. Zhang X, Zheng H, Zhang H, et al. Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke. Cytokine 2011; 56: 717-725.
84. Van Maele L, Carnoy C, Cayet D, et al. Activation of type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis 2014; 210: 493-503.
85. Pichavant M, Sharan R, Le Rouzic O, et al. IL-22 defect during Streptococcus pneumoniae infection triggers exacerbation of chronic obstructive pulmonary disease. EBioMedicine 2015; 2: 1686-1696.
86. Le Rouzic O, Koné B, Kluza J, et al. Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response. Respir Res 2016; 17: 94.
87. Liao S-X, Ding T, Rao X-M, et al. Cigarette smoke affects dendritic cell maturation in the small airways of patients with chronic obstructive pulmonary disease. Mol Med Rep 2015; 11: 219-225.
88. Sichelstiel A, Yadava K, Trompette A, et al. Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PLoS One 2014; 9: e98440.
89. Paget C, Ivanov S, Fontaine J, et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J Biol Chem 2012; 287: 8816-8829.
90. Guillon A, Jouan Y, Brea D, et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. Eur Respir J 2015; 46: 771-782.
91. Wiehler S, Proud D. Interleukin-17A modulates human airway epithelial responses to human rhinovirus infection. Am J Physiol Lung Cell Mol Physiol 2007; 293: L505-L515.
92. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 1117-1124.
93. Guinea J, Sandoval-Denis M, Escribano P, et al. Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions. J Clin Microbiol 2015; 53: 611-617.
94. Delsuc C, Cottereau A, Frealle E, et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. Crit Care 2015; 19: 421.
95. Jolink H, de Boer R, Hombrink P, et al. Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells. J Infect 2017; 74: 81-88.
96. Werner JL, Gessner MA, Lilly LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infect Immun 2011; 79: 3966-3977.
97. Camargo JF, Bhimji A, Kumar D, et al. Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis. PLoS One 2015; 10: e0123171.
98. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008; 451: 211-215.
99. Murdock BJ, Falkowski NR, Shreiner AB, et al. Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infect Immun 2012; 80: 1424-1436.
100. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013; 12: 543-559.
101. Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med 2016; 11: 8.
102. van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75: 83–98.e4.
103. Vyas P, Vohora D. Innovative targets for asthma and COPD: exploring the existing and screening the new!! Infect Disord Drug Targets 2016; 16: 162–171.
104. Liljevald M, Rehnberg M, Söderberg M, et al. Retinoid-related orphan receptor γ (RORγ) adult induced knockout mice develop lymphoblastic lymphoma. Autoimmun Rev 2016; 15: 1062–1070.
105. Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest 2015; 148: 1164–1176.
106. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014; 505: 412–416.
107. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015–1026.
108. Brightling C, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193–198.
109. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138.
110. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435–442.
111. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662–671.